Histone Methyltransferases Smyd2: The Potential Pharmacological Target On Cancers And Aging-Related Diseases Treatment
Our bodies have intricate ways of controlling how our genes work, not by changing the genes themselves, but by adding tiny chemical tags to proteins associated with our DNA. This process is called epigenetics, and one crucial player in this system is a group of enzymes known as histone methyltransferases. These enzymes act like molecular decorators, adding methyl groups (small chemical tags) to proteins, which can then influence whether a gene is turned “on” or “off.”
One such enzyme, called SMYD2, has recently caught the attention of researchers. It plays a significant role in adding these methyl tags to various proteins, both those directly linked to our DNA (histones) and other proteins within our cells. Scientists have found that when SMYD2 doesn’t function correctly, it can contribute to the development and progression of serious health issues, including different types of cancers and conditions that arise as we age.
Because of its involvement in these diseases, SMYD2 is now considered a promising target for new medications. The idea is to design drugs that can specifically block or modify the activity of SMYD2, thereby correcting the abnormal gene regulation that contributes to these illnesses. While the full extent of SMYD2’s biological roles is still being uncovered, and the development of specific inhibitors is in its early stages, this research opens up exciting possibilities for creating innovative therapies to combat cancer and improve health in aging populations.
Source: link to paper